Solventum Corporation

Solventum trades at a 7.43 P/E—a stark discount that suggests meaningful undervaluation relative to the broader healthcare technology space. The stock sits comfortably neutral at RSI 45.3, neither oversold nor overbought, while sitting well below its 52-week high. With only 4.33% short interest, there's minimal squeeze potential but also limited bearish conviction. The valuation multiple implies the market has priced in significant headwinds or expects moderate growth. This setup presents a classic value trap question: is the low multiple justified by earnings challenges, or does it signal genuine opportunity in a surgical instruments player with stable fundamentals?